


PHARMACEUTICAL 2022



REGENERON PHARMACEUTICALS INC.



Rank 8 of 475





PHARMACEUTICAL 2022



REGENERON PHARMACEUTICALS INC.



Rank 8 of 475

The relative strengths and weaknesses of REGENERON PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of REGENERON PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 531% points. The greatest weakness of REGENERON PHARMACEUTICALS INC. is the variable Other Expenses, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 332%, being 609% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	14,014,900
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,932,500
Liabilities, Non-Current	2,733,500
Other Assets	11,419,900
Other Compr. Net Income	-55,500
Other Expenses	3,642,400
Other Liabilities	0
Other Net Income	379,000
Property and Equipment	0
Research and Development	2,908,100
Revenues	16,071,700
Selling, General and Administrative Expense	1,824,900

Output Variable	Value in 1000 USD
Assets	25,434,800
Liabilities	6,666,000
Expenses	8,375,400
Stockholders Equity	18,768,800
Net Income	8,075,300
Comprehensive Net Income	8,047,550
Economic Capital Ratio	332%